[Adjuvant chemotherapy in breast cancer: status in 1984].
Postoperative adjuvant chemotherapy prolongs the recurrence-free interval and, probably, overall survival in patients with surgically-treated, node-positive breast cancer. Composition, dosage, timing and duration of cytostatic treatment are not yet standardized. Among node-negative patients those with a relatively high risk of recurrence (receptor negative) should also be given adjuvant chemotherapy. Combination with endocrine treatment and/or radiotherapy merits further investigation. We need more large, well-designed controlled clinical studies to answer the numerous unsolved questions on this subject.
D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008207:Lymphatic Metastasis / Q000175:diagnosis; D008408:Mastectomy; D008593:Menopause; D008727:Methotrexate / Q000627:therapeutic use; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D013997:Time Factors
D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Adjuvante Chemotherapie beim Mammakarzinom: stand 1984.